Office of clinical pharmacology - new task order #4 against spaulding clinical studies IDIQ 75F40119D10032 - clinical ECG studies to evaluate electrophysiological effects of potential QT prolonging…
Ended Awarded Last action
- Contract number
- 75F40121F19004
- Awardee
-
Spaulding Clinical Research, LLC UEI HERBKHMPKQN5
- Awarding agency
-
Food and Drug Administration
Department of Health and Human Services
- Obligated
- $1,429,138
Award facts
- Opportunity
-
- FDA21RFTOP1243183 Solicitation number
- Contract value 100% obligated
- $1,429,138.43 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- Contracting staff
- NAICS code
- 541714 Research and Development in Biotechnology (except Nanobiotechnology)
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- West Bend, WI 53095, USA
Award details come from SAM.gov/FPDS.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Other Administrative Action | $163,077 | |
| Other Administrative Action | $0 | |
| Original award | $1,266,061 |
About this award
This $1,429,138.43 firm fixed price delivery order was awarded to Spaulding Clinical Research, LLC by the Food and Drug Administration (FDA), a civilian agency of the U.S. government. The delivery order was issued under Spaulding's $30 million Indefinite Delivery Indefinite Quantity (IDIQ) contract with the FDA for clinical and laboratory applied regulatory science services.
The delivery order is for clinical electrocardiogram (ECG) studies to evaluate the electrophysiological effects of potential QT prolonging drugs using novel ECG biomarkers. This work supports the FDA's regulatory science programs and assists in regulatory decision-making across product lifecycles. Spaulding will perform the ECG studies at its facilities in West Bend, Wisconsin and Silver Spring, Maryland, with an ultimate completion date of October 10, 2024. This delivery order was not set aside for any particular business type.
Description
Office of clinical pharmacology - new task order #4 against spaulding clinical studies IDIQ 75F40119D10032 - clinical ECG studies to evaluate electrophysiological effects of potential QT prolonging drugs with novel ECG biomarkers
Quick answers
Who was awarded contract 75F40121F19004?
75F40121F19004 was awarded to Spaulding Clinical Research, LLC by Food and Drug Administration (Department of Health and Human Services) on September 10, 2021.
How much is contract 75F40121F19004 worth?
The government has obligated $1,429,138 on 75F40121F19004.
Is contract 75F40121F19004 an order under another contract?
Yes. 75F40121F19004 is a delivery order under 75F40119D10032, an indefinite delivery contract.
Was contract 75F40121F19004 competed?
The extent of competition for 75F40121F19004 was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award